GT Biopharma Appoints New Member to its Board of Directors
MWN-AI** Summary
GT Biopharma, Inc., a San Francisco-based clinical-stage immuno-oncology company, recently announced a significant change to its Board of Directors. On May 14, 2025, the Company appointed Hilary Kramer to the board, filling the vacancy left by Bruce Wendel, who has resigned. This strategic move comes as GT Biopharma continues to make advancements in its proprietary TriKE® natural killer (NK) cell engager platform, which is designed to enhance the immune system's ability to combat cancer.
Michael Breen, the Executive Chairman and CEO of GT Biopharma, expressed enthusiasm about Kramer's appointment, highlighting her solid strategic and operational background as a valuable asset during this pivotal phase of the company's growth. With her extensive experience, Kramer is expected to play a crucial role in guiding the company through its ongoing clinical development efforts.
Kramer brings a wealth of financial and investment expertise to the board, having founded GreenTech Research, the first U.S.-based sustainable investment fund. With a history of serving on multiple public company boards and experience managing large family office portfolios, her background includes prior roles at Freddie Mac and investment banking at Lehman Brothers and Morgan Stanley. Kramer holds a B.A. in Political Science and Latin American Studies from Wellesley College, as well as an MBA from the Wharton School of the University of Pennsylvania.
GT Biopharma, which is focused on the development and commercialization of immuno-oncology therapeutics, has exclusive licensing rights to further develop its TriKE® technology in partnership with the University of Minnesota. As the company progresses, Kramer's leadership is anticipated to enhance its strategic direction and operational execution in the competitive biotech landscape.
MWN-AI** Analysis
GT Biopharma, Inc. (NASDAQ: GTBP) recently made headlines with the appointment of Hilary Kramer to its Board of Directors, a strategic move that signals an important transition for the company. Such changes in leadership can often influence market perception and investor sentiment dramatically, making it a critical moment for current and prospective shareholders.
Mrs. Kramer's seasoned background in finance and investment management, particularly as the Founder and Chief Investment Officer of GreenTech Research, reinforces the company’s commitment to robust financial oversight and strategic growth. Her extensive experience in both public and private sectors, coupled with a strong academic foundation, suggests that she will bring valuable insights into GT Biopharma’s development and commercialization strategies, particularly for its proprietary TriKE® natural killer (NK) cell engager platform.
From an investment perspective, this leadership change could catalyze positive momentum. The biopharmaceutical sector is known for volatility, and successful board appointments often provide a re-energized vision that can lead to enhanced market performance. Kramer's past involvement with high-profile companies presents an opportunity for GT Biopharma to tap into her expansive network, potentially opening doors for partnerships or collaborations that can expedite clinical trials or commercialization of its therapies.
However, investors should remain cautious. The press release includes standard forward-looking statements, underscoring inherent risks in biopharmaceutical ventures, such as regulatory hurdles and market competition. Active monitoring of GT Biopharma’s progress in clinical trials will be essential, as advancements in the development of their TriKE® technology could significantly impact stock performance.
In conclusion, while the appointment of Hilary Kramer is promising and positions GT Biopharma for a potentially lucrative phase, investors need to stay vigilant about the associated risks in a dynamic market landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE ® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position.
“We are delighted to welcome Hilary to the Board of Directors at this exciting time, and we look forward to leveraging her expertise as we continue to make great clinical progress with our NK engagers,” said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. “Hilary is an experienced executive with a strong strategic and operational background. She is an important addition to the board as the Company evolves in its next phase of maturation as a clinical stage biotech company.”
Mrs. Kramer is the Founder and Chief Investment Officer of GreenTech Research, the very first U.S.-based sustainable fund and publisher of growth equity research and global market forecasting. She actively oversees portfolio strategy, positioning, hedging, and fund allocations. Mrs. Kramer has served on the boards of several public companies, including RSL Communications Ltd., Deltathree Inc., El Sitio Inc., and INX Digital, and was a member of the Advisory Boards for DirecTV International and Ibero-American Media Partners.
Previously, she was Senior Managing Director and Chief Investment Officer for a $12 billion family office portfolio, where she developed the investment strategy, managed diversified equity and fixed-income portfolios, and directed private equity investments. She has been a consultant at Freddie Mac, Montgomery Asset Management and to families offices. Her earlier career includes investment banking at Lehman Brothers and Morgan Stanley, as well as brand management at General Mills. Mrs. Kramer holds a B.A. with honors in Political Science and Latin American Studies from Wellesley College and an MBA from the Wharton School of the University of Pennsylvania.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell engager platform. Our TriKE ® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE ® technology. For more information, please visit gtbiopharma.com .
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE ® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
FAQ**
How does Hilary Kramer's extensive investment background enhance the strategic direction of GT Biopharma Inc. (GTBP) as it progresses with its TriKE ® platform?
What specific clinical milestones does GT Biopharma Inc. (GTBP) aim to achieve in the next year following Hilary Kramer's appointment to the Board of Directors?
In what ways does GT Biopharma Inc. (GTBP) plan to leverage its exclusive license agreement with the University of Minnesota in advancing its NK cell engager technology?
Given the potential risks outlined in the forward-looking statements, what contingency plans does GT Biopharma Inc. (GTBP) have in place to address uncertainties in its clinical development timeline?
**MWN-AI FAQ is based on asking OpenAI questions about GT Biopharma Inc. (NASDAQ: GTBP).
NASDAQ: GTBP
GTBP Trading
-7.18% G/L:
$0.4084 Last:
1,935,580 Volume:
$0.4508 Open:
